Delving into the Latest Updates on BAT-7205 with Synapse

Overview

Basic Info

Drug Type

Antibody fusion proteins

Synonyms

BAT7205

Target

IL-15 x PDL1

Mechanism

IL-15 modulators(Interleukin-15 modulators), PDL1 modulators(Programmed death-ligand 1 modulators)

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid Neoplasm

Inactive Indication-

Originator Organization

Bio-Thera Solutions, Ltd.

Active Organization

Bio-Thera Solutions, Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价BAT7205 的安全性和耐受性，探索最大耐受剂量（MTD），为后续临床研究提供合理的给药方案。次要目的：评价BAT7205 的药代动力学（PK）特征；初步评价BAT7205 的抗肿瘤活性；评价BAT7205 的免疫原性；评价程序性死亡配体1 （ PDL1）表达水平与BAT7205 抗肿瘤活性的相关性。

[Translation]

Primary objective: To evaluate the safety and tolerability of BAT7205, explore the maximum tolerated dose (MTD), and provide a reasonable dosing regimen for subsequent clinical studies. Secondary objectives: To evaluate the pharmacokinetic (PK) characteristics of BAT7205; To preliminarily evaluate the anti-tumor activity of BAT7205; To evaluate the immunogenicity of BAT7205; To evaluate the correlation between the expression level of programmed death ligand 1 (PDL1) and the anti-tumor activity of BAT7205.

Start Date15 Apr 2024

Sponsor / Collaborator